T3S Technologies

T3S Technologies is a private biotechnology firm focused on overcoming the significant challenge of expressing difficult recombinant proteins. Its core platform integrates three proprietary technologies: a high-speed bacterial secretion system (T3S), advanced codon context optimization, and a vast library of optimized bacterial strains. Founded by leading microbial geneticists, the company appears to be in a pre-revenue or early-revenue stage, providing expression services and leveraging grant funding (e.g., NSF) while building its technological foundation. Its primary business model is a mix of platform technology development and contract research services.

Proprietary bacterial protein expression platform integrating three core technologies: 1) A Type III Secretion (T3S) system for high-speed extracellular secretion of cytotoxic/insoluble proteins, 2) Codon context optimization for enhanced translation efficiency, and 3) A large library of optimized, engineered bacterial strains.

T3S competes in a crowded field of protein expression CROs and technology providers, including giants like Thermo Fisher and Merck, as well as specialized firms. Its differentiation is its focused claim on 'difficult-to-express' proteins via a novel bacterial secretion mechanism. Success depends on proving superior efficacy for specific high-value targets where standard E. coli and even other alternative systems fail.